Efficacy and Safety of Tiselizumab Combined with Anlotinib and 2-cycle Irinotecan as Second-line Treatment of Small Cell Lung Cancer

被引：0

作者：

Chen, X. ^{[1
]}

Zhang, H. ^{[1
]}

Li, Y. ^{[1
]}

Liu, L. ^{[1
]}

Qu, X. ^{[1
]}

机构：

[1] Guangzhou Univ Tradit Chinese, Guangzhou, Peoples R China

来源：

JOURNAL OF THORACIC ONCOLOGY | 2022年 / 17卷 / 09期

关键词：

Small Cell Lung Cancer; Immune checkpoint inhibitors; Efficacy and Safety;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

EP14.01-00

引用

页码：S527 / S527

页数：1

共 50 条

[21] Efficacy and Safety of Anlotinib in the Treatment of Small Cell Lung Cancer: A Real-World Observation Study [J].

Yuan, Jing ;

Cheng, Feng ;

Xiao, Guodong ;

Wang, Xiaofeng ;

Fan, Huijie .

FRONTIERS IN ONCOLOGY, 2022, 12

[22] Second-line chemotherapy for small-Cell Lung Cancer (SCLC) [J].

Kim, Young Hak ;

Mishima, Michiaki .

CANCER TREATMENT REVIEWS, 2011, 37 (02) :143-150

[23] Real-world efficacy and safety of anlotinib as third- or further-line treatment in refractory small cell lung cancer [J].

Xuetian Gao ;

Ling Peng ;

Li Zhang ;

Kai Huang ;

Cuihua Yi ;

Bei Li ;

Xue Meng ;

Jisheng Li .

Journal of Cancer Research and Clinical Oncology, 2022, 148 :2661-2671

[24] RESILIENT Part 2: A phase 3 Study of Liposomal Irinotecan in Patients with Small-Cell Lung Cancer in the Second-Line Setting [J].

Paz-Ares, L. ;

Spigel, D. R. ;

Chen, Y. ;

Jove, M. ;

Juan-Vidal, O. ;

Rich, P. ;

Hayes, T. ;

Gutierrez Calderon, V. ;

Caro, R. B. ;

Navarro Mendivil, A. ;

Dowlati, A. ;

Zhang, B. ;

Moore, Y. ;

Wang, T. ;

Kokhreidze, J. ;

Ponce, S. ;

Bunn, P. .

JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) :S505-S505

[25] Sacituzumab Govitecan as Second-Line Treatment in Patients with Extensive Stage Small Cell Lung Cancer [J].

Dowlati, A. ;

Chiang, A. C. ;

Cervantes, A. ;

Babu, S. ;

Hamilton, E. ;

Wong, S. F. ;

Tazbirkova, A. ;

Sullivan, I. G. ;

van Marcke, C. ;

Italiano, A. ;

Patel, J. ;

Mekan, S. ;

Wu, T. ;

Waqar, S. N. .

JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) :S16-S16

[26] Cytostatic treatment in small cell lung cancer. Induction, maintenance, and second-line therapy [J].

Niederle, N. ;

Deppermann, K. -M. ;

Wolf, M. .

ONKOLOGE, 2008, 14 (08) :783-+

[27] A Systematic Analysis of Efficacy of Second-Line Chemotherapy in Sensitive and Refractory Small-Cell Lung Cancer [J].

Owonikoko, Taofeek K. ;

Behera, Madhusmita ;

Chen, Zhengjia ;

Bhimani, Chandar ;

Curran, Walter J. ;

Khuri, Fadlo R. ;

Ramalingam, Suresh S. .

JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (05) :866-872

[28] Efficacy and safety of Cadonilimab plus anlotinib in small cell lung cancer with brain metastases [J].

Yi, Hai-Zhen ;

Lv, Wei ;

Chen, Jin-Jing ;

Lin, Zhan .

FRONTIERS IN ONCOLOGY, 2025, 15

[29] Phase Ib/II study on the safety, tolerability, and preliminary efficacy of pegylated irinotecan (JK1201I) as second-line monotherapy for patients with small-cell lung cancer [J].

Long, Jieran ;

Li, Xuefei ;

Wu, Lin ;

Yu, Guohua ;

Zang, Aimin ;

Zhao, Yanqiu ;

Shi, Jinsheng ;

Nie, Ligong ;

Zhao, Xuan ;

Fang, Jian .

CANCER MEDICINE, 2024, 13 (17)

[30] Efficacy of different monotherapies in second-line treatment for small cell lung cancer: a meta-analysis of randomized controlled trials [J].

Luo, Qiuping ;

Wang, Ziwei ;

Li, Shengjie ;

Zhou, Jianying .

INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2015, 8 (10) :19689-19700

← 1 2 3 4 5 →